Related Experiment Video
Updated: Jan 12, 2026
08:25
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
11.7K
Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions
Al-Yafie Shikaha Ahmed Y1, Lee Wei Shyn1, Pong Ben Jun Xiang1
1Sunway Biofunctional Molecules Discovery Centre, Faculty of Medical and Life Sciences, Sunway University. No 5, Jalan Universiti, Petaling Jaya, Malaysia.
Asia-Pacific Journal of Clinical Oncology
|October 30, 2025
Summary
Liquid biopsy offers a less invasive alternative to tissue biopsy for hematologic malignancies. Biomarkers like circulating tumor DNA (ctDNA) aid in diagnosis, therapy, and monitoring of these cancers.
Area of Science:
- Hematology
- Oncology
- Genomics
Background:
- Hematologic malignancies affect blood, bone marrow, and lymphatics.
- Traditional tissue biopsy for genomic profiling is invasive and costly.
- Liquid biopsy is an emerging, less invasive diagnostic tool.
Purpose of the Study:
- To review advancements in liquid biopsy biomarkers for hematologic malignancies.
- To assess the effectiveness of liquid biopsy in diagnosis, therapy, and monitoring.
- To discuss challenges and future directions for liquid biopsy in this field.
Main Methods:
- Literature review of recent advancements in liquid biopsy.
- Analysis of liquid biopsy biomarkers such as ctDNA, miRNA, and exosomes.
- Examination of their role in hematologic malignancy management.
Main Results:
- Liquid biopsy biomarkers provide insights into disease etiology.
- Differential expression patterns enable effective disease monitoring.
- Liquid biopsy aids in guiding treatment decisions for hematologic cancers.
Conclusions:
- Liquid biopsy shows significant promise for hematologic malignancies.
- It offers a valuable tool for diagnosis, therapy, and monitoring.
- Further research is needed to address current challenges and optimize future applications.
